TXN Systems, a Solna, Sweden-based pharmaceutical company developing a first-in-class antibiotic for multidrug-resistant urinary tract infections, raised SEK25M in Series A Funding.
Backers included Mikael Lönn, MD and Jens Mogensen, alongside GU Ventures, Vasa Angels, Annexstruktur, as well as from Gobia Enterprises.
The company intends to use the funds to support the development of EbsArgent™, the company’s first-in-class bactericidal antibiotic for urinary tract infections (UTIs) caused by antibiotic-resistant bacteria.
Led by CEO Elias Arnér, MD, PhD, Thioredoxin Systems AB (TXN Systems) is a pharmaceutical company developing an antibiotic to treat multidrug-resistant urinary tract infections. Its patented EbsArgent™, a combination drug containing silver ions and the compound ebselen, has a novel mechanism of action that uses ebselen to disable the essential bacterial thioredoxin enzyme system and silver ions to synergistically enhance ebselen uptake, to fight bacterial infections in new ways and without triggering resistance.
FinSMEs
30/10/2024